移至標頭移至導覽移至內部移至註腳

研究成果 (3)

排序依據：日期 | 題名

10 | 25 | 50 | 100

上一頁

上一頁

1/1

下一頁

最後一頁

A B C E H I O P T Y 從論全部

Is Danggui safe to be taken by breast cancer patients? - A skepticism finally answered by comprehensive preclinical evidence
Yue GGL, Wong LS, Leung HW, Gao S, Tsang JYS, Lin ZX, Law BKB, Tse GMK, Lau CBS ( 2019 )
FRONTIERS IN PHARMACOLOGY
Publication in refereed journal
典藏於此文庫的全文:
Yue GGL et al 2019_Is Danggui safe to be taken by breast cancer patients - A skepticism finally answered by comprehensive preclinical evidence.pdf
數位物件識別號 (DOI): http://dx.doi.org/10.3389/fphar.2019.00706
Isorhynchophylline ameliorates cognitive impairment via modulating amyloid pathology, tau hyperphosphorylation and neuroinflammation: Studies in a transgenic mouse model of Alzheimer's disease
Li HQ, Ip SP, Yuan QJ, Zheng GQ, Tsim KKW, Dong TTX, Lin G, Han Y, Liu Y, Xian YF, Lin ZX ( 2019 )
Brain, behavior, and immunity
Publication in refereed journal
數位物件識別號 (DOI): http://dx.doi.org/10.1016/j.bbi.2019.08.194
Isorhynchophylline exerts antidepressant-like effects in mice via modulating neuroinflammation and neurotrophins: involvement of the PI3K/Akt/GSK-3 beta signaling pathway
Xian, Ip, Li, Qu, Su, Chen, Lin ( 2019 )
FASEB journal : official publication of the Federation of American Societies for Experimental Biology
Publication in refereed journal
數位物件識別號 (DOI): http://dx.doi.org/10.1096/fj.201802743RR

10 | 25 | 50 | 100

上一頁

上一頁

1/1

下一頁

最後一頁